Information about the expected shortage of the medicinal product Tarka 180 mg/2 mg tablets with modified release (verapamil, trandolapril) and the medicinal product Tarka 240 mg/4 mg tablets with modified release (verapamil, trandolapril)
02.08.2012
Abbott laboratories d.o.o., the marketing authorisation holder forthe medicinal product Tarka 180 mg/2 mg tablets with modified release (verapamil, trandolapril) and the medicinal product Tarka 240 mg/4 mg tablets with modified release (verapamil, trandolapril) has informed the Agency for Medicinal Products and Medical Devices about the shortage of the aforementioned products onthe Croatian market. The aforementioned products belong to the group of medicines that are used to lower blood pressure (antihypertensives). The shortage is caused by a manufacturing delay at the Abbott GmbH & Co. KG manufacturing site in Ludwigshafen, Germany.
The supply normalisation of the market with the medicinal product Tarka 180 mg/2 mg tablets with modified release and the medicinal product Tarka 240 mg/4 mg tablets with modified release is expected in September 2012.
The public will be promptly informed about any new information on the availability of the medicinal product Tarka 180 mg/2 mg tablets with modified release and the medicinal product Tarka 240 mg/4 mg tablets with modified release
